Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 18Esophageal Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Esophageal Squamous Cell Carcinoma 11Uterine Cervical Neoplasms 9Head and Neck Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Pancreatic Neoplasms 8Stomach Neoplasms 4Neoplasms 3Colorectal Neoplasms 3Recurrence 2Pancreatic cancer, adult 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Diffuse Intrinsic Pontine Glioma 2Carcinoma 2Adenocarcinoma 2Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Anal Canal 1Solid Tumors 1Solid Tumor 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Nasopharyngeal Diseases 1NSCLC 1

Interventions

Sorafenib 2nimotuzumab 1lenvatinib 1atezolizumab 1Tirapazamine 1Radiotherapy 1Radiosurgery 1Radiofrequency Ablation 1Immune Checkpoint Inhibitors 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HCC × nimotuzumab × Clear all
NCT06413017 2024-05-14

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled

HCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡